SCHEMBL8965

SCHEMBL8965

CC(C)(C)CCCC(N)=O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SOAT1 P35610 2/20 0.37
KMT2A Q03164 2/20 0.37
TP53 P04637 2/20 0.37
CYP1A2 P05177 2/20 0.37
CYP3A4 P08684 2/20 0.37
CYP2C19 P33261 2/20 0.37
MEN1 O00255 1/20 0.37
FAAH O00519 1/20 0.37
CNR1 P21554 1/20 0.34
KDM4E B2RXH2 3/20 0.33
LMNA P02545 3/20 0.32
ALDH1A1 P00352 2/20 0.32
HSD17B10 Q99714 2/20 0.32
ALOX15 P16050 4/20 0.32
BLM P54132 3/20 0.32
PMP22 Q01453 3/20 0.32
TDP1 Q9NUW8 2/20 0.32
FFAR1 O14842 1/20 0.32
CPT2 P23786 1/20 0.32
GMNN O75496 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9065 0.92 KMT2A (0.40) SOAT1KMT2ATP53CYP1A2CYP3A4
SCHEMBL156750 0.90 SOAT1 (0.43) SOAT1KMT2ATP53CYP1A2CYP3A4
SCHEMBL22271556 0.90 SOAT1 (0.43) SOAT1KMT2ATP53CYP1A2CYP3A4
SCHEMBL10722958 0.90 SOAT1 (0.43) SOAT1KMT2ATP53CYP1A2CYP3A4
SCHEMBL3479319 0.90 SOAT1 (0.43) SOAT1KMT2ATP53CYP1A2CYP3A4
SCHEMBL10721246 0.90 SOAT1 (0.43) SOAT1KMT2ATP53CYP1A2CYP3A4
Hydrochloric Acid SCHEMBL31484801 0.87 SOAT1 (0.42) SOAT1KMT2ATP53CYP1A2CYP3A4
SCHEMBL179561 0.86
SCHEMBL31480046 0.85 KMT2A (0.36) SOAT1KMT2ATP53CYP1A2CYP3A4
Hydrochloric Acid SCHEMBL29184596 0.83 LMNA (0.32) SOAT1KMT2ATP53CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4237086-A1 HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE Amgen Inc. (US) 2023-09-06 EP claimed
WO-2022093856-A1 HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE AMGEN INC. (US) 2022-05-05 WO claimed
CN-106459004-B Apelin receptor (APJ) agonists and uses thereof 研究三角协会 2020-09-15 CN claimed
US-20190125701-A1 Compositions and Methods for Treating Viral Infection in Mammals UNIV YALE (US) 2019-05-02 US claimed
EP-3452172-A1 COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTION IN MAMMALS Yale University (US) 2019-03-13 EP claimed
WO-2017192799-A1 COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTION IN MAMMALS YALE UNIVERSITY (US) 2017-11-09 WO claimed
WO-2011000945-A2 AMINOALKAMIDES FOR USE IN THE TREATMENT OF INFLAMMATORY, DEGENERATIVE OR DEMYELINATING DISEASES OF THE CNS NENSIUS RESEARCH A/S (DK) 2011-01-06 WO claimed
CN-118344372-A Substituted straight-chain spiro derivatives 詹森药业有限公司 2024-07-16 CN disclosed
CN-118255774-A Substituted straight-chain spiro derivatives 詹森药业有限公司 2024-06-28 CN disclosed
CN-118255773-A Substituted straight-chain spiro derivatives 詹森药业有限公司 2024-06-28 CN disclosed
WO-2024054811-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-14 WO disclosed
US-20230330254-A1 ANTI-GLP1R ANTIBODY-TETHERED DRUG CONJUGATES COMPRISING GLP1 PEPTIDOMIMETICS AND USES THEREOF REGENERON PHARMACEUTICALS, INC. (US) 2023-10-19 US disclosed
EP-4237086-A1 HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE Amgen Inc. (US) 2023-09-06 EP disclosed
US-20100298270-A1 Novel Compounds and Methods of Using Them SYNDAX PHARMACEUTICALS, INC. (US) 2010-11-25 US disclosed
US-6967196-B1 Sulfonamide compounds and uses thereof BRISTOL-MYERS SQUIBB COMPANY (US) 2005-11-22 US disclosed
EP-0677038-B1 METHOD FOR AMIDE PREPARATION EXXON CHEMICAL PATENTS INC (US) 1998-07-08 EP disclosed
EP-0827507-A1 PROTEASE INHIBITING SUCCINIC ACID DERIVATIVES BOEHRINGER INGELHEIM (CANADA) LTD. (CA) 1998-03-11 EP disclosed
WO-1996031527-A1 PROTEASE INHIBITING SUCCINIC ACID DERIVATIVES BOEHRINGER INGELHEIM (CANADA) LTD./BOEHRINGER INGELHEIM (CANADA) LTÉE. (CA) 1996-10-10 WO disclosed
US-5153327-A 7-Oxabicycloheptyl substituted heterocyclic amide or ester prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease E. R. SQUIBB & SONS, INC. (US) 1992-10-06 US disclosed
US-5100889-A Thromboxane A2 receptor antagonists, thromboxane synthetase inhibitor E. R. SQUIBB & SONS, INC. (US) 1992-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298270-A1 Novel Compounds and Methods of Using Them HDAC1, HDAC3, HDAC6 SOAT1 1195/4885KMT2A 49/4885TP53 2351/4885
US-20230330254-A1 ANTI-GLP1R ANTIBODY-TETHERED DRUG CONJUGATES COMPRISING GLP1 PEPTIDOMIMETICS AND USES THEREOF GLP1R, GIPR, GCGR SOAT1 320/4885KMT2A 1978/4885TP53 4176/4885
US-20190125701-A1 Compositions and Methods for Treating Viral Infection in Mammals RPL35, PIGS, HAVCR2 SOAT1 4723/4885KMT2A 1060/4885TP53 215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.